Fenoterol / Ipratropium inhaler
Therapeutic agent (verify pharmacological class)
What it is used for
Bronchospasm associated with acute severe exacerbations of bronchial asthma or chronic obstructive pulmonary disease (COPD). Clinical selection for Fenoterol / Ipratropium inhaler should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC. Class context: Therapeutic agent (verify pharmacological class). Confirm site-specific dose, duration and monitoring before prescribing.
Warnings
Obtain allergy and medication history. Adjust for renal/hepatic impairment, pregnancy, lactation, extremes of age and interacting drugs. Use the lowest effective dose for the shortest appropriate duration. Monitor for expected class adverse effects.
Possible side effects
Tremor of skeletal muscles, dry mouth, nervousness, tachycardia, increased heart rate, dizziness, palpitations or headache, hypokalemia, allergic reactions, pharyngitis, throat irritation, bad taste, and vomiting.
Storage
Store as labelled. Keep out of reach of children.
No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.